<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4741">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746602</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-241010</org_study_id>
    <nct_id>NCT01746602</nct_id>
  </id_info>
  <brief_title>Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects</brief_title>
  <official_title>Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long term treatment with anti-glaucomatous drugs has been shown to increase the incidence of
      dry eye syndrome with all known consequences such as ocular discomfort and epithelial
      keratitis. Given that thinning of the tear film appears to be a risk factor for the
      development or the aggravation of dry eye syndrome, the current study seeks to investigate
      whether tear film thickness is changed after topical treatment with anti-glaucomatous drugs
      in healthy subjects.

      For this purpose, tear film thickness will be measured at baseline and after single
      instillation of one of 5 study drugs in one randomly chosen eye. In addition, one group of
      20 subjects will receive no drug and will serve as a second control. Drug effects on tear
      film thickness will be compared to the fellow, non-treated eye. In addition, effects on tear
      film thickness of timolol with preservatives (Timoptic 0.5%) will be compared to timolol
      without preservatives (Timophtal sine 0.5%) and three lubricants with different viscosity
      (Genteal HA, Hylo-Comod, Thealoz).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Tear film thickness</measure>
    <time_frame>up to  1 hour</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Break up time (BUT)</measure>
    <time_frame>once on the study day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>healthy subjects I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects VI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timoptic® 0.5%</intervention_name>
    <description>Timoptic® 0.5% Eye Drops, Merck, single instillation</description>
    <arm_group_label>healthy subjects I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timophtal sine® 0.5%</intervention_name>
    <description>Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation</description>
    <arm_group_label>healthy subjects II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genteal HA®</intervention_name>
    <description>Genteal HA® Eye Drops, Novartis, single instillation</description>
    <arm_group_label>healthy subjects III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hylo-Comod®</intervention_name>
    <description>Hylo-Comod® Eye Drops, Croma-Pharma, single instillation</description>
    <arm_group_label>healthy subjects IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thealoz®</intervention_name>
    <description>Thealoz® Eye Drops, Thea, France, single instillation</description>
    <arm_group_label>healthy subjects V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 years

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

          -  Normal ophthalmic findings, ametropia &lt; 6 Dpt.

        Exclusion Criteria:

          -  Regular use of medication (except contraceptives), abuse of alcoholic beverages,
             participation in a clinical trial in the 3 weeks preceding the study

          -  Treatment in the previous 3 weeks with any drug

          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day

          -  Patients with known hypersensitivity to the study drug or any ingredients

          -  History or current COPD or asthma

          -  AV-block grade II or more

          -  Ametropy ≥ 6 Dpt

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Garhoefer, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>2981</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>2981</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Gerhard Garhoefer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>topical lubricants</keyword>
  <keyword>tear film thickness</keyword>
  <keyword>anti-glaucoma drugs</keyword>
  <keyword>break up time</keyword>
  <keyword>anti-glaucoma treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
